Get complete Patent Opposition Report for Genmab

Comprehensive Analysis, Strategic Insights & Expert Evaluation – Stay Ahead in Your Patent Challenge.

Download Your Report Now

Latest oppositions filed by Genmab

Explore patent oppositions filed by Genmab against competitors, revealing strategic technology disputes and market positioning. Monitor opposition details, timelines, and disputed innovations to understand competitive dynamics and IP enforcement strategy.

Patent NumberTitleApplicantOpposition Date
EP3656443Use Of Trl Agonist And Anti-Cd47 Agent To Enhance Phagocytosis Of Cancer CellsTHE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITYJun 29, 2022
EP3177645Subcutaneously Administered Bispecific Antibodies For Use In The Treatment Of CancerLINDHOFERNov 17, 2021
EP3056514Methods For Manipulating Phagocytosis Mediated By Cd47THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITYJan 17, 2020
EP3056515Methods For Manipulating Phagocytosis Mediated By Cd47THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITYJan 17, 2020
EP2970493Methods For Achieving Therapeutically Effective Doses Of Anti-Cd47 AgentsTHE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITYJan 3, 2020
EP2647707Cytotoxicity-Inducing Therapeutic AgentCHUGAI SEIYAKU KABUSHIKI KAISHAJun 12, 2019

Explore Genmab's recently opposed patents, revealing key competitive challenges and strategic patent disputes in the industry. Track oppositions filed by competitors to understand technology battlegrounds and assess potential risks.

Patent NumberGrant DateTitleTotal Oppositions
EP3319996Jan 3, 2024Bispecific And Multispecific Antibodies And Method For Isolation Of Such2
EP2943507Feb 26, 2020Inert Format2
EP3312196Jul 17, 2019Antibodies Against Cd38 For Treatment Of Multiple Myeloma1
EP2535355Jan 2, 2019Antibodies Against Cd38 For Treatment Of Multiple Myeloma1
EP2076769Apr 25, 2018High Througput Methods For Characterization Of Antibodies1